Pfizer optimistic about drug candidates in late-stage development

04/2/2009 | Wall Street Journal, The · Reuters

In a periodic update, Pfizer presented a positive outlook for some of its drugs entering late-stage development, including a JAK inhibitor for rheumatoid arthritis, Alzheimer's disease drug Dimebon and Tanezumab, a monoclonal antibody to treat pain. In a separate announcement, the company said it is halting a trial of Sutent after the cancer medicine failed to outperform chemotherapy drug capecitabine in improving patients' condition.

View Full Article in:

Wall Street Journal, The · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ